Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer

  • Deal value of up to US$525 million
  • Novo Holdings co-led ReViral Series B financing in 2018
  • ReViral developing novel antiviral therapies to treat RSV infections
  • Validation of Novo Holdings’ strategy to identify and invest in high quality European biotech opportunities

Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, today announces that its portfolio company ReViral Ltd (ReViral), has entered into a definitive agreement to be acquired by Pfizer (NYSE: PFE) for up to US$525 million in total deal value.

Read more